BioNTech

Biotechnology sector market performance

3 clusters · 8 sources · last updated 2 days ago

Latest: Biotech stocks reach 52-week highs amid clinical updates and portfolio shifts

The biotechnology sector has experienced significant volatility and growth driven by clinical trial developments and financial reporting. In late August 2026, the market showed contrasting trends. BioNTech shares fell 8

BioNTech lung cancer clinical trial developments

2 clusters · 13 sources · last updated 3 days ago

Latest: BioNTech reports positive lung cancer clinical trial data

BioNTech has reported positive results from clinical trials targeting lung cancer. In the Phase 3 PRESERVE-003 study, the experimental antibody Gotistobart (BNT316/ONC-392), developed with U.S.-based OncoC4, showed a med

Cancer immunotherapy research and access challenges

3 clusters · 10 sources · last updated 5 days ago

Latest: Cancer therapy advances face significant access challenges

Recent research into cancer immunotherapy has focused on understanding side effects, treatment timing, and the influence of other vaccines on patient outcomes. Initial studies identified that inflammatory arthritis caus

US FDA COVID-19 vaccine updates

3 clusters · 27 sources · last updated 12 days ago

Latest: COVID-19 cases rise across 47 U.S. states

The U.S. Food and Drug Administration (FDA) has approved updated COVID-19 vaccines for the 2026-2027 season to target the XFG subvariant of the JN.1 coronavirus lineage. The approved vaccines include mRNA formulations fr

BioNTech restructuring, oncology shift, revenue cut

11 clusters · 42 sources · last updated 18 days ago

Latest: BioNTech halts personalized mRNA colorectal cancer vaccine trial

In August 2026, BioNTech significantly reduced its full-year revenue outlook to €1.6–1.9 billion, down from a previous target of €2.0–2.3 billion, citing declining COVID-19 vaccine demand and lost milestone payments. The